Floatz logo

Pembrolizumab

Richter Transformation

Roswell Park Cancer Institutemonoclonal_antibodyPhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
81/ 100

Competitive context

56 Active assets in the Richter Transformation cohort.

Asset / SponsorPhaseRating
Obinutuzumab
Christine Ryan
Phase 2BB
Venetoclax
Northwestern University
Phase 2BB
Ibrutinib
City of Hope Medical Center
Phase 2BB
Cyclophosphamide
SWOG Cancer Research Network
Phase 3BB
PREDNISONE TABLETS
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →